An experienced investor recommends the Schwab U.S. Dividend Equity ETF (SCHD) as the foundational holding for a new portfolio. The ETF focuses on high-yielding dividend-growth stocks and has delivered over 12% average annualized returns over multiple periods, outperforming pure growth stocks and high-yield stocks with lower volatility.

AbbVie, a pharmaceutical company spun off from Abbott in 2013, maintains Dividend King status with an attractive 2.7% yield well above industry averages. Despite a high earnings payout ratio of 330%, the company's cash flow-based payout ratio of 60% indicates a sustainable dividend. AbbVie's strong portfolio includes blockbuster drugs like Botox and newer immunology treatments (Skyrizi and Rinvoq) that offset patent expirations. The company's recent $11 billion acquisition of Apogee further strengthens its pipeline in inflammatory and immunological diseases.

The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.

AbbVie has demonstrated strong recovery after Humira's patent loss, with immunology drugs Skyrizi and Rinvoq exceeding sales expectations and not facing biosimilar competition until 2033. The company maintains a promising pipeline including weight-loss therapy ABBV-295 and acquired eczema treatment zumilokibart. AbbVie's Dividend King status with 203.5% dividend increases over the past decade and a 2.7% yield makes it an attractive long-term investment despite near-term headwinds from Humira decline and Imbruvica pricing pressure.

The Schwab U.S. Dividend Equity ETF (SCHD) has returned approximately 20% in 2026, outperforming both the S&P 500 and Nasdaq-100. The $95 billion fund focuses on companies with at least 10 consecutive years of dividend payments and screens for quality fundamentals. Its concentration in healthcare and consumer staples has benefited from a market rotation away from expensive AI and software stocks, though the fund's long-term job is delivering growing income from durable businesses rather than outrunning growth indexes.

Tech stocks extended their sell-off on July 16, 2026, with the Nasdaq Composite falling 1.47% amid growing AI spending concerns and escalating U.S.-Iran tensions. Micron Technology plunged nearly 6%, while semiconductor leaders like Nvidia and Broadcom declined. Taiwan Semiconductor Manufacturing fell despite record earnings. Abbott Laboratories surged over 10% on strong earnings. A Bank of America survey revealed 45% of fund managers view an AI bubble as the largest market risk.

The semiconductor sector continued its fourth consecutive day of losses after Taiwan Semiconductor raised capital expenditure forecasts to $60-64 billion, sparking investor concerns about profitability. Memory chip stocks like SK Hynix and Micron plummeted, dragging down the Nasdaq and S&P 500. The Dow remained relatively stable as healthcare stocks, particularly UnitedHealth and Abbott Laboratories, rallied on strong earnings, offsetting tech sector weakness.

The global biochemistry analyzer market is projected to reach $8.18 billion by 2035, driven by increasing diagnostic testing demand, adoption of fully automated systems, artificial intelligence integration, and rising preventive screening programs. The market encompasses various product types, modalities, and applications across hospitals, diagnostic centers, and research institutions globally.

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.

The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.

AbbVie, a Dividend King, is acquiring Apogee Therapeutics for $10.9 billion to strengthen its drug pipeline and maintain its dividend growth streak. The deal brings late-stage drug candidates like zumilokibart for atopic dermatitis and respiratory drugs, helping AbbVie replace revenue lost from Humira's patent expiration with newer products like Skyrizi and Rinvoq.

Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.